Table 3 Subgroup Analysis
Iron treatment in case period(%) | Iron treatment in control period 1 + 2 + 3(%) | Odds ratio (95% CI) | P-value | P-value for interaction | |
|---|---|---|---|---|---|
Heart failure | 0.710 | ||||
Yes | 27 (6.2%) | 76 (5.8%) | 1.070 (0.680, 1.684) | 0.769 | |
No | 40 (4.1%) | 125 (4.3%) | 0.958 (0.666, 1.379) | 0.818 | |
Chronic lung disease | 0.607 | ||||
Yes | 17 (5.4%) | 45 (4.7%) | 1.141 (0.643, 2.024) | 0.652 | |
No | 50 (4.6%) | 156 (4.8%) | 0.960 (0.693, 1.330) | 0.805 | |
Diabetes Mellitus | 0.940 | ||||
Yes | 44 (5.2%) | 131 (5.1%) | 1.008 (0.710, 1.432) | 0.964 | |
No | 23 (4.1%) | 70 (4.2%) | 0.985 (0.609, 1.594) | 0.951 | |
Venous catheter for HD | 0.976 | ||||
Yes | 0 (0%) | 7 (4.8%) | 0.000 (< 0.001, > 99.99) | 0.952 | |
No | 67 (4.9%) | 194 (4.8%) | 1.038 (0.781, 1.380) | 0.796 | |
Iron > 300 mg/month | 0.391 | ||||
Yes | 25 (21%) | 86 (23%) | 0.839 (0.508, 1.386) | 0.493 | |
No | 42 (3.3%) | 115 (3.0%) | 1.099 (0.767, 1.574) | 0.607 | |